A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture

Virology

Volumn 248, Issue 2, 1998, Pages 382-393

  Cihlar, Tomas ^a   Fuller, Michael D ^a   Mulato, Andrew S ^a   Cherrington, Julie M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET;

AMINO ACID SUBSTITUTION; ARTICLE; BASE PAIRING; CROSS RESISTANCE; CYTOMEGALOVIRUS; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; VIRUS EXPRESSION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALIA; CANINE DISTEMPER VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5; RNA VIRUSES;

EID: 0032169622     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9299     Document Type: Article

References (52)

1. Anders D. G., Kacica M. A., Pari G., Punturieri S. M. Boundaries and structure of human cytomegalovirusori. J. Virol. 66:1992;3373-3384.
2. Baldanti F., Sarasini A., Silini E., Barbi M., Lazzarin A., Biron K. K., Gerna G. Four dually resistant human cytomegalovirus strains from AIDS patients: Single mutation in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand. J. Infect. Dis. Supl. 99:1995a;103-104.
3. Baldanti F., Underwood M. R., Stanat S. C., Biron K. K., Chou S., Sarasini A., Silini E., Gerna G. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1996;1390-1395.
4. Baldanti F., Underwood M. R., Talarico C., Simoncini L., Sarasini A., Biron K. K., Gerna G. The Cys607 to Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents Chemother. 42:1998;444-446.
5. Bernad A., Blanco L., Lazaro J. M., Martin G., Salas M. A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell. 59:1989;219-228.
6. Biron, K. K. Baldanti, F. 1996, Nucleosides and foscarnet: Mechanisms, In, Antiviral Drug Resistance, 125, 152, John Wiley & Sons Ltd. New York.
7. Blanco L., Bernad A., Blasco M. A., Salas M. A general structure for DNA-dependent DNA polymerases. Gene. 100:1991;27-38.
8. Cherrington J. M., Miner R., Hitchcock M. J. M., Lalezari J. P., Drew W. L. Susceptibility of human cytomegalovirus (HCMV) to cidofovir is unchanged after limitedin vivo. J. Infect. Dis. 173:1996;987-992.
9. Cherrington J. M., Fuller M. D., Lamy P. D., Miner R., Lalezari J. P. In vitro. J. Infect. Dis. 1998.
10. Chou S., Erice A., Jordan M. C., Vercellotti G. M., Michels K. R., Talarico C. L., Stanat S. C., Biron K. K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:1995;576-583.
11. Chou S., Marousek G., Guentzel S., Follansbee S. E., Poscher M. E., Lalezari J. P., Miner R. C., Drew W. L. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:1997;786-789.
12. Chrisp P., Clissold S. P. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 41:1991;104-129.
13. Cihlar T., Chen M. S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their acitivities in host cells. Mol. Pharmacol. 50:1996;1502-1510.
14. Cihlar T., Fuller M. D., Cherrington J. M. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupledin vitro. Protein Expression Purif. 11:1997;209-218.
15. Cihlar T., Fuller M. D., Cherrington J. M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:1998;5927-5936.
16. Cleland W. W. Statistical analysis of enzyme kinetic data. Methods Enzymol. 63:1979;103-138.
17. Crumpacker C. S. Ganciclovir. Drug Therapy. 335:1996;721-729.
18. Dorsky D. D., Crumpacker C. S. Expression of herpes simplex virus type 1 DNA polymerase gene by in vitro translation and effect of gene deletions on activity. J. Virol. 62:1988;3224-3232.
19. Echols H., Goodman M. F. Fidelity mechanism in DNA replication. Annu. Rev. Biochem. 60:1991;477-511.
20. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:1989;289-293.
21. Ertl P. F., Powell K. L. Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein ICP36 expressed in insect cells. J. Virol. 66:1992;4126-4133.
22. Hall J. D., Orth K. L., Sander K. L., Swihart B. M., Senese R. A. Mutations within conserved motifs in the 3′-5′ exonuclease domain of herpes simplex virus DNA polymerase. J. Gen. Virol. 76:1995;2999-3008.
23. Hwang C. B. C., Ruffner K. L., Coen D. M. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J. Virol. 66:1992;1774-1776.
24. Hwang Y. T., Liu B.-Y., Coen D. M., Hwang C. B. C. Effects of mutations in the ExoIII motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J. Virol. 71:1997;7791-7798.
25. Ito J., Braithwaite D. K. Compilation and alignment of DNA polymerase sequences. Nucleic Acids Res. 19:1991;4045-4057.
26. Jacobson M. A., Mills J. Serious cytomegalovirus disease in the acquired imunodeficiency syndrome (AIDS): Clinical findings, diagnosis, and treatment. Ann. Intern. Med. 108:1988;585-594.
27. Kühn F. J. P., Knopf C. W. Herpes simplex virus type 1 DNA polymerase: Mutational analysis of the 3′-5′ exonuclease domain. J. Biol. Chem. 271:1996;29245-29254.
28. Lalezari J. P. Cidofovir: A new therapy for cytomegalovirus retinitis. J. AIDS Human Retrovirol. 14:1997;S22-S26.
29. Littler E., Stuart A. D., Chee M. S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 358:1992;160-162.
30. Lurain N. S., Thompson K. D., Holmes E. W., Read G. S. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:1992;7146-7152.
31. Mar E.-C., Chiou J.-F., Cheng Y.-C., Huang E.-S. Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 53:1985a;776-780.
32. Mar E.-C., Chiou J.-F., Cheng Y.-C., Huang E.-S. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy-2′fluoro-β-D-arabinofuranosyl)-5-methyluracil,-5- iodocytosine, and -5-methylcytosine. J. Virol. 53:1985b;846-851.
33. Morrison A., Bell J. B., Kunkel T. A., Sugino A. Eukaryotic DNA polymerase amino acid sequence required for 3′-5′ exonuclease activity. Proc. Natl. Acad. Sci. USA. 88:1991;9473-9477.
34. Öberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 40:1989;213-285.
35. Pair G. S., Anders D. G. Eleven loci encodingtransori. J. Virol. 67:1993a;6979-6988.
36. Pari G. S., Kacica M. A., Anders D. G. Open reading frames UL44, IRS1/TRS1, and UL36-38 are required for transient complementation of human cytomegalovirusori. J. Virol. 67:1993b;2575-2582.
37. Rubin R. H. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12:1990;S754-S766.
38. Simon M., Giot L., Faye G. The 3′-5′ exonuclease activity located in the DNA polymerase δ subunit ofSaccharomyces cerevisiae. EMBO J. 10:1991;2165-2170.
39. Smee D. F., Barnett B. B., Sidwell R. W., Reist E. J., Holy A. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antiviral Res. 25:1995;1-9.
40. Smith I. L., Cherrington J. M., Jiles R. E., Fuller M. D., Freeman W. R., Spector S. A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:1997;69-77.
41. Snoeck R., Andrei G., De Clercq E. Patterns of resistance and sensitivity to antiviral compounds of drug resistant strains of human cytomegalovirus selectedin vitro. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;574-579.
42. J. Infect. Dis. 176:1997;50-58.
43. Sullivan V., Talarico C. L., Stanat S. C., Davis M., Coen D. M., Biron K. K. A protein kinase homologue controls phosphorylation of ganciclovir in cytomegalovirus-infected cells. Nature. 358:1992;162-164.
44. Sullivan V., Biron K. K., Talarico C. L., Stanat S. C., Davis M., Pozzi L. M., Coen D. M. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:1993;19-25.
45. Tenney D. J., Yamanaka G., Voss S. M., Cianci C. W., Tuomari A. V., Sheaffer A. K., Alam M., Colonno R. J. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemother. 41:1997;2680-2685.
46. Weiland K. L., Oien N. L., Homa F., Wathen M. W. Functional analysis of human cytomegalovirus polymerase accessory protein. Virus Res. 34:1994;191-206.
47. Wolf D. G., Smith I. L., Lee D. J., Freeman W. R., Flores-Aguilar M., Spector S. A. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Invest. 95:1995;257-263.
48. Wong S. W., Wahl A. F., Yuan P.-M., Arai N., Pearson B. E., Arai K.-I., Korn D., Hunkapiller M. W., Wang T. S.-F. Human DNA polymerase α gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases. EMBO J. 7:1988;37-47.
49. Xiong X., Flores C., Fuller M. D., Mendel D. B., Mulato A. S., Moon K., Chen M. S., Cherrington J. M. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir). Antiviral Res. 36:1997a;131-137.
50. Xiong X., Smith J. L., Chen M. S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:1997b;594-599.
51. Ye L. B., Huang E. S. In vitro expression of the human cytomegalovirus DNA polymerase gene: Effects of sequence alterations on enzyme activity. J. Virol. 67:1993;6339-6347.
52. Zhang J., Chung D. W., Tan C.-K., Downey K. M., Davie E. W., So A. G. Primary structure of the catalytic subunit of calf thymus DNA polymerase δ: Sequence similarities with other DNA polymerases. Biochemistry. 30:1991;11742-11750.